摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3,5,6,7,8-hexahydro-3-amino-2-thioxo<1>benzothieno<2,3-d>pyrimidin-4(1H)-one potassium salt

中文名称
——
中文别名
——
英文名称
2,3,5,6,7,8-hexahydro-3-amino-2-thioxo<1>benzothieno<2,3-d>pyrimidin-4(1H)-one potassium salt
英文别名
2,3,5,6,7,8-hexahydro-3-amino-2-thioxo[1]benzothieno[2,3-d]pyrimidin-4(1H)-one potassium salt;Potassium;3-amino-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidine-2-thiolate
2,3,5,6,7,8-hexahydro-3-amino-2-thioxo<1>benzothieno<2,3-d>pyrimidin-4(1H)-one potassium salt化学式
CAS
——
化学式
C10H10N3OS2*K
mdl
——
分子量
291.439
InChiKey
BBQPSJCSMHOCOA-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.04
  • 重原子数:
    17
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    87.9
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • [[(Arylpiperazinyl)alkyl]thio]thieno[2,3-<i>d</i>]pyrimidinone Derivatives as High-Affinity, Selective 5-HT<sub>1A</sub> Receptor Ligands
    作者:Maria Modica、Maria Santagati、Filippo Russo、Luca Parotti、Luca De Gioia、Carlo Selvaggini、Mario Salmona、Tiziana Mennini
    DOI:10.1021/jm950866t
    日期:1997.2.1
    l)alkyl]thio]thieno[2,3-d]pyrimidin-4 (1H)-one and 3-substituted 2-[[(4-aryl-1-piperazinyl)alky]thio]thieno[2,3-d]pyrimidin-4 (3H)-one derivatives was prepared and evaluated for in vitro 5-HT1A receptor affinity by radioligand binding assays; the selectivity for 5-HT1A receptors rather than alpha 1-adrenoceptors was also examined (ratio of the IC50 alpha 1 to IC50 5-HT1A). The binding tests gave indications
    一系列2-[[((4-芳基-1-哌嗪基)烷基]硫代]噻吩并[2,3-d]嘧啶-4(1H)-和3-取代的2-[[((4-芳基-1)制备了-哌嗪基)烷基]硫代]噻吩并[2,3-d]嘧啶-4(3H)-衍生物,并通过放射性配体结合试验评估了其在体外对5-HT1A受体的亲和力。还检查了5-HT1A受体而不是α1-肾上腺素受体的选择性(IC50α1与IC50 5-HT1A之比)。结合测试表明了[(芳基哌嗪基)烷基]硫基部分的最佳特征以及有效和选择性的5-HT1A配体的噻吩和嘧啶酮环上的取代基。从大鼠海马膜上置换[3H] -8-OH-DPAT的最有效衍生物是3-氨基-2-[[3- [4-(2-(2-甲氧基苯基)-1-哌嗪基]丙基]硫基] -5 ,6-二甲基噻吩并[2,3-d]嘧啶-4(3H)-一(70)(IC50 = 0。3 nM),对5-HT1A的选择性比α1-肾上腺素能受体高24。N4哌嗪环上的2-
  • Discovery of a Novel 5-HT<sub>3</sub> Antagonist/5-HT<sub>1A</sub> Agonist 3-Amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3<i>H</i>)-one (TZB-30878) as an Orally Bioavailable Agent for Irritable Bowel Syndrome
    作者:Akira Asagarasu、Teruaki Matsui、Hiroyuki Hayashi、Satoru Tamaoki、Yukinao Yamauchi、Kouichi Minato、Michitaka Sato
    DOI:10.1021/jm1002292
    日期:2010.11.11
    We have prepared a series of quinazolinone derivatives linked with piperazinylquinoline for the treatment of irritable bowel syndrome (IBS). Using pharmacophore analysis, we designed and synthesized compounds which bind to both serotonin receptor subtype 1A (5-HT1A) and subtype 3 (5-HT3). Quinazolinone derivatives with a sulfur atom in the linker showed high affinity in in vitro assays, but low in vivo activity. Focusing on the linker to improve the pharmacokinetic profile, the sulfur atom in the linker was replaced with a methylene group. Further optimization led to the discovery of compound 17m (TZB-30878) (J. Pharmacol. Exp. Ther. 2007, 322, 1315-1323, Patent WO2005082887 (A1), 2005), a novel 5-HT1A agonist/5-HT3 antagonist in the 3-aminoquinazolinone series. In in vivo functional assays, 17m dose dependently inhibited the Bezold-Jarisch reflex and induced 5-HT1A-mediated behaviors, and in an IBS animal model, 17m significantly inhibited stress-induced defecation. Pretreatment by WAY-100635 (5-HT1A antagonist) significantly attenuated but did not abolish the inhibitory effects of 17m. These results suggested that 17m exerted inhibitory effects via both 5-HT1A agonistic and 5-HT3 antagonistic activities and that 17m would be useful as a therapeutic agent for IBS.
  • Santagati, Andrea; Modica, Maria; Santagati, Maria, Journal of Heterocyclic Chemistry, <hi>1994</hi>, vol. 31, # 5, p. 1141 - 1144
    作者:Santagati, Andrea、Modica, Maria、Santagati, Maria
    DOI:——
    日期:——
  • Synthesis of 2,3,5,6,7,8-Hexahydro-3-amino-2-thioxo[1]benzothieno[2,3-d]pyrimidin-4(1H)-one and Derivatives of the New Heterocyclic System 7,8,9,10-Tetrahydro-3H,11H-[1]benzothieno[2',3':4,5]pyrimido[2,1-b][1,3,4]thiadiazin-11-one
    作者:Andrea Santagati、Maria Santagati、Maria Modica
    DOI:10.3987/com-92-6304
    日期:——
    A versatile compound, 2,3,5,6,7,8-hexahydro-3-amino-2-thioxo[1]benzothieno [2,3-d]pyrimidin-4(1H)-one (4), was synthesized from ethyl 4,5,6,7-tetrahydro-2-isothiocyanato-1-benzothiophene-3-carboxylate(1). Derivatives of a heterocyclic linear system having the 1,3,4-thiadiazine ring were obtained from the key intermediate (4).
  • Santagati, Andrea; Modica, Maria; Santagati, Maria, Journal of Heterocyclic Chemistry, 1994, vol. 31, # 5, p. 1141 - 1144
    作者:Santagati, Andrea、Modica, Maria、Santagati, Maria
    DOI:——
    日期:——
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇 7-溴噻吩并[3,2-d]嘧啶 7-溴噻吩并[3,2-D]嘧啶-4(1H)-酮 7-溴-噻吩并[3,2-d]嘧啶-4-胺 7-溴-4-氯噻酚并[3,2-D]嘧啶 7-溴-2-氯噻吩并[3,2-D]嘧啶